La Jolla enters agreement with Stanford University La Jolla Pharmaceutical announced that it has signed an option agreement with Leland Stanford Junior University that will add proprietary technology to the company’s programs. The option agreement with Stanford allows La Jolla to test the technology potentially adding product opportunities to La Jolla’s pipeline. La Jolla is currently testing novel oral formulations using the technology in an animal model of Non-alcoholic Steatohepatitis. If successful, these product candidates will add to the company’s pipeline.
News For LJPC From The Last 14 Days
Check below for free stories on LJPC the last two weeks.
La Jolla files to sell common stock, no amount given La Jolla intends to use the net proceeds from the underwritten offering for general corporate purposes, funding its ongoing and future clinical trials, general and administrative expenses and potential future acquisitions and other strategic purposes. Jefferies LLC is acting as sole book-runner for the offering.